Multiplexing Ability

Testing for multiple DNA mutations simultaneously in a single test

Cancers often have multiple actionable DNA mutations for which there are specifically designed drugs, and therefore a clinically useful test panel should have the ability to test simultaneously for all these multiple mutations in one sample. Only MutantDx’s patents permit simultaneous testing at femtogram concentrations for multiple mutations with verifiable accuracy.
Reference 6

Typical Multiplexed Result Showing Two Mutations
Detection of NRAS 61R and NRAS 61L Colorectal Cancer

This allows three powerful operational advantages over competing methods:

  • A complete Liquid Biopsy test panel for all actionable mutations that have specifically designed drugs
  • A lower cost per reported result than competing technologies
  • Additional QA Targets are built into every mutation assay for the detection of false positive and false negative results

Dr Roger Hodkinson


MutantDx Inc.

17204 106A Avenue
Edmonton, Alberta
Canada T5S 1E6